Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. It may also stimulate the immune system in different ways and stop
tumor cells from growing.
PURPOSE: This phase I trial is studying the side effects and best dose of celecoxib in
treating patients with stage IIIB or stage IV non-small cell lung cancer.